Anticoagulants, Antiplatelets, and Thrombolytics:
During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and inven...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Springer New York
2004
|
| Schriftenreihe: | Methods In Molecular Medicine™
93 |
| Schlagworte: | |
| Online-Zugang: | UBR01 TUM01 Volltext |
| Zusammenfassung: | During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases |
| Beschreibung: | 1 Online-Ressource (X, 310 p) |
| ISBN: | 9781592596584 |
| DOI: | 10.1385/1592596584 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV044951056 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 180517s2004 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592596584 |9 978-1-59259-658-4 | ||
| 024 | 7 | |a 10.1385/1592596584 |2 doi | |
| 035 | |a (ZDB-2-PRO)978-1-59259-658-4 | ||
| 035 | |a (OCoLC)1184486121 | ||
| 035 | |a (DE-599)BVBBV044951056 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 082 | 0 | |a 616.15 |2 23 | |
| 245 | 1 | 0 | |a Anticoagulants, Antiplatelets, and Thrombolytics |c edited by Shaker A. Mousa |
| 264 | 1 | |a Totowa, NJ |b Springer New York |c 2004 | |
| 300 | |a 1 Online-Ressource (X, 310 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods In Molecular Medicine™ |v 93 | |
| 520 | |a During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases | ||
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a Hematology | |
| 650 | 4 | |a Medicine | |
| 650 | 4 | |a Hematology | |
| 700 | 1 | |a Mousa, Shaker A. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781588290830 |
| 856 | 4 | 0 | |u https://doi.org/10.1385/1592596584 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-PRO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030343815 | ||
| 966 | e | |u https://doi.org/10.1385/1592596584 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1385/1592596584 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804178539220566016 |
|---|---|
| any_adam_object | |
| author2 | Mousa, Shaker A. |
| author2_role | edt |
| author2_variant | s a m sa sam |
| author_facet | Mousa, Shaker A. |
| building | Verbundindex |
| bvnumber | BV044951056 |
| collection | ZDB-2-PRO |
| ctrlnum | (ZDB-2-PRO)978-1-59259-658-4 (OCoLC)1184486121 (DE-599)BVBBV044951056 |
| dewey-full | 616.15 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.15 |
| dewey-search | 616.15 |
| dewey-sort | 3616.15 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1385/1592596584 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02891nmm a2200421zcb4500</leader><controlfield tag="001">BV044951056</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">180517s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592596584</subfield><subfield code="9">978-1-59259-658-4</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1385/1592596584</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-59259-658-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1184486121</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044951056</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.15</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anticoagulants, Antiplatelets, and Thrombolytics</subfield><subfield code="c">edited by Shaker A. Mousa</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 310 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods In Molecular Medicine™</subfield><subfield code="v">93</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine & Public Health</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hematology</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mousa, Shaker A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781588290830</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1385/1592596584</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030343815</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592596584</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592596584</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV044951056 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:05:35Z |
| institution | BVB |
| isbn | 9781592596584 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030343815 |
| oclc_num | 1184486121 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (X, 310 p) |
| psigel | ZDB-2-PRO |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Springer New York |
| record_format | marc |
| series2 | Methods In Molecular Medicine™ |
| spelling | Anticoagulants, Antiplatelets, and Thrombolytics edited by Shaker A. Mousa Totowa, NJ Springer New York 2004 1 Online-Ressource (X, 310 p) txt rdacontent c rdamedia cr rdacarrier Methods In Molecular Medicine™ 93 During the past decade, remarkable progress has been made in the development of new drugs to treat thrombotic and cardiovascular diseases, the number one cause of mortality worldwide. In Anticoagulants, Antiplatelets, and Thrombolytics, leading experts with established records of discovery and invention highlight the latest developments in antithrombotics and provide experimental methods for the discovery of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as hirudin, and such antiplatelet drugs as the GPIIb/IIIa inhibitors and ADP-receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue-factor targeting, platelet-receptor targeting, and antithrombin III modulation. The authors also define the clinically relevant in vitro and in vivo models of thrombosis and hemostasis that led to these advances and that will surely aid in the discovery of the next generation of antithrombotics. Up-to-date and forward-looking, Anticoagulants, Antiplatelets, and Thrombolytics illuminates the latest developments in the field of thrombosis and provides both basic and clinical investigators a broad array of successful experimental methods for the discovery and development of novel drugs to treat thrombotic and cardiovascular diseases Medicine & Public Health Hematology Medicine Mousa, Shaker A. edt Erscheint auch als Druck-Ausgabe 9781588290830 https://doi.org/10.1385/1592596584 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Anticoagulants, Antiplatelets, and Thrombolytics Medicine & Public Health Hematology Medicine |
| title | Anticoagulants, Antiplatelets, and Thrombolytics |
| title_auth | Anticoagulants, Antiplatelets, and Thrombolytics |
| title_exact_search | Anticoagulants, Antiplatelets, and Thrombolytics |
| title_full | Anticoagulants, Antiplatelets, and Thrombolytics edited by Shaker A. Mousa |
| title_fullStr | Anticoagulants, Antiplatelets, and Thrombolytics edited by Shaker A. Mousa |
| title_full_unstemmed | Anticoagulants, Antiplatelets, and Thrombolytics edited by Shaker A. Mousa |
| title_short | Anticoagulants, Antiplatelets, and Thrombolytics |
| title_sort | anticoagulants antiplatelets and thrombolytics |
| topic | Medicine & Public Health Hematology Medicine |
| topic_facet | Medicine & Public Health Hematology Medicine |
| url | https://doi.org/10.1385/1592596584 |
| work_keys_str_mv | AT mousashakera anticoagulantsantiplateletsandthrombolytics |